flowchart TD
VY7523["VY7523"]
AD["Alzheimers Disease"]
VY7523 -->|"targets"| AD
style VY7523 fill:#81c784,stroke:#333,color:#000
style AD fill:#ef5350,stroke:#333,color:#000
VY7523 is an investigational recombinant humanized IgG4 monoclonal antibody developed by [Voyager Therapeutics](https://ir.voyagertx.com) in a Phase 1/2 clinical trial for early [Alzheimer's disease](/diseases/alzheimers-disease) (AD)[@nct06874621]. The antibody targets a novel mechanism of neurodegenerative pathology distinct from established amyloid-beta (Abeta) or tau targets["@voyager_pipeline"]. The trial enrolls approximately 52 patients in a multiple ascending dose (MAD) study design.
Voyager Therapeutics is a biotechnology company focused on developing gene therapy and antibody-based treatments for severe neurological diseases. Their platform combines adeno-associated virus (AAV) delivery technology with novel therapeutic antibodies, enabling potent CNS penetration and sustained target engagement["@brunden_2021"].
Trial Details
| Parameter | Value | |-----------|-------| | Trial ID | NCT06874621 | | Sponsor | Voyager Therapeutics | | Phase | Phase 1/2 | | Status | Active, recruiting | | Study Type | Interventional | | Indication | Early Alzheimer's Disease | | Enrollment | Approximately 52 participants | | Start Date | 2024 | | Study Design | Multiple ascending dose (MAD) |
Mechanism of Action
...
VY7523 Voyager AD NCT06874621
Overview
Mermaid diagram (expand to render)
VY7523 is an investigational recombinant humanized IgG4 monoclonal antibody developed by [Voyager Therapeutics](https://ir.voyagertx.com) in a Phase 1/2 clinical trial for early [Alzheimer's disease](/diseases/alzheimers-disease) (AD)[@nct06874621]. The antibody targets a novel mechanism of neurodegenerative pathology distinct from established amyloid-beta (Abeta) or tau targets["@voyager_pipeline"]. The trial enrolls approximately 52 patients in a multiple ascending dose (MAD) study design.
Voyager Therapeutics is a biotechnology company focused on developing gene therapy and antibody-based treatments for severe neurological diseases. Their platform combines adeno-associated virus (AAV) delivery technology with novel therapeutic antibodies, enabling potent CNS penetration and sustained target engagement["@brunden_2021"].
Trial Details
| Parameter | Value | |-----------|-------| | Trial ID | NCT06874621 | | Sponsor | Voyager Therapeutics | | Phase | Phase 1/2 | | Status | Active, recruiting | | Study Type | Interventional | | Indication | Early Alzheimer's Disease | | Enrollment | Approximately 52 participants | | Start Date | 2024 | | Study Design | Multiple ascending dose (MAD) |
Mechanism of Action
VY7523 is a humanized IgG4 monoclonal antibody designed to target a specific epitope involved in neurodegenerative pathways characteristic of Alzheimer's disease. The antibody-mediated targeting approach enables selective engagement of pathological proteins or aggregates contributing to neuronal dysfunction[@logovinsky_2016].
Target Pathway
While the precise molecular target is proprietary to Voyager's development program, the antibody-based approach suggests engagement with one or more of the following pathogenic mechanisms:
Pathological protein aggregation: Targeting misfolded or aggregated proteins that drive neuronal toxicity in AD[@hardy_2006]
Synaptic dysfunction: Interference with mechanisms that disrupt synaptic integrity and communication between neurons[@schenk_2021]
Neuroinflammation: Modulation of inflammatory cascades that accelerate neurodegeneration
Antibody Engineering
The IgG4 isotype of VY7523 offers specific advantages for CNS therapeutic applications:
Improved safety profile: The reduced inflammatory potential may offer a more favorable risk-benefit ratio compared to IgG1 antibodies with high effector function
Voyager Therapeutics has built a proprietary gene therapy platform based on AAV vector technology capable of crossing the blood-brain barrier and achieving broad CNS transduction[@brunden_2021]. While VY7523 is delivered as a traditional monoclonal antibody (not AAV-mediated gene therapy), the company's expertise in CNS antibody engineering informs the antibody design:
CNS Penetrance Optimization
Voyager's experience with AAV delivery of therapeutic proteins has informed their approach to antibody engineering for CNS targets:
Engineering of antibody properties to enhance blood-brain barrier (BBB) penetration
Optimization of FcRn-mediated recycling to extend half-life
Selection of epitope regions accessible in the CNS compartment
Platform Synergy
VY7523 represents a strategic expansion of Voyager's CNS antibody capabilities, complementing their AAV-based gene therapy pipeline for neurodegenerative diseases. The antibody modality offers:
Predictable pharmacokinetics and dosing
Well-characterized safety profile from extensive prior antibody development
Reversible target engagement if safety concerns arise
Faster path to clinical proof-of-concept compared to gene therapy
Clinical Development Context
Alzheimer's Disease Antibody Landscape
VY7523 enters a rapidly evolving AD antibody therapeutics field marked by recent approvals and clinical advances[@van_dyck_2023]: